A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Status:
Recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
This study was a phase Ib study of the safety and pharmacokinetics/pharmacodynamics of F-627
once per cycle as prophylaxis therapy to chemotherapy in women with breast cancer.
The patients received the intravenous administration of the chemotherapy (docetaxol,
doxorubicin and cyclophosphamide, 75 mg/m2, 50 mg/m2 and 500 mg/m2 respectively) on Day 1
and the subcutaneous injection of F-627 at 240 µg/kg and 320 µg/kg on Day 2 (approximately
24 hours after chemotherapy) each cycle for up to 6 cycles.